Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Alamar Biosciences, Inc. (ALMR)

Alamar Biosciences adds Robert Ragusa to board, effective September 1, 2026

Neutral Impact 2 of 5 leadership Written later

Alamar Biosciences appointed Robert Ragusa to its board of directors, effective September 1, 2026, as a Class I director with a term expiring at the 2027 annual meeting. He also joined the audit, compensation, and nominating and corporate governance committees. The filing describes this as a routine board addition with no related person transactions disclosed.

Key points

  • Robert Ragusa appointed to the Board by action on August 28, 2026, effective September 1, 2026
  • Class I director; initial term expires at the 2027 Annual Meeting of Stockholders
  • Also named to Audit, Compensation, and Nominating and Corporate Governance Committees
  • Compensated under the Non-Employee Director Compensation Policy described in the April 17, 2026 final prospectus

The filing

CompanyAlamar Biosciences, Inc. (ALMR)
Form8-K, current report
Filed with the SECSep 1, 2026, 4:01 PM ET
Accession number0001193125-26-378360

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 11:48 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 01, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.